Stage II nasopharyngeal carcinoma: adding induction chemo to CCRT does not improve prognosis

  • Jin T & al.
  • Transl Oncol
  • 16 Nov 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The addition of induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) is associated with similar survival outcomes to CCRT alone in patients with stage II nasopharyngeal carcinoma (NPC).

Why this matters

  • A previous study using a smaller sample size had shown negative effects on survival with IC, but in this study the treatment regimen is not significantly associated with survival.

Key results

  • 5-year DFS was 85.1% and 5-year OS was 93.2%.
  • CCRT with IC was associated with a lower 5-year DFS (80.6% vs 88.5%) rate compared with CCRT alone, although this difference was not significant in multivariate analysis (HR, 1.047; P=.057).
  • CCRT with IC was associated with similar 5-year OS compared with CCRT alone (90.5% vs 95.0%; P=.375).
  • Adding IC to CCRT was associated with higher incidence of grade 3/4 hematological toxic effects (23.6% vs 6.4%; P<.001 grade liver dysfunction vs p and kidney compared with ccrt alone.>

Study design

  • 445 patients with stage II NPC, 195 treated with IC and CCRT and 250 treated with CCRT alone, were analyzed.
  • Funding: Zhejiang Province, National Natural Science Foundation of China, Zhejiang Cancer Hospital.

Limitations

  • Retrospective study.